References
- Burzykowski T, Molenberghs G, Buyse M. The Evaluation of Surrogate Endpoints. Springer-Verlag, NY, USA (2005).
- Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin. Pharmacol. Ther.69, 89–95 (2001).
- Ellenberg SS, Hamilton JM. Surrogate endpoints in clinical trials: cancer. Stat. Med.8, 405–413 (1989).
- Fleming TR, DeMets DL. Surrogate endpoints in clinical trials: are we being misled? Ann. Intern. Med.125, 605–613 (1996).
- Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Preliminary report: effect of encainide and ecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infraction. N. Engl. J. Med.321, 406–412 (1989).
- De Gruttola V, Tu XM. Modelling progression of CD-4 lymphocyte count and its relationship to survival time. Biometrics50, 1003–1014 (1995).
- Lagakos SW, Hoth DF. Surrogate markers in AIDS: where are we? Where are we going? Ann. Intern. Med.116, 599–601 (1992).
- De Gruttola V, Fleming TR, Lin DY, Coombs R. Validating surrogate markers – are we being naive? J. Infect. Dis.175, 237–246 (1997).
- Fleming TR. Surrogate endpoints in clinical trials. Drug Inf. J.30, 545–551 (1996).
- Ferentz AE. Integrating pharmacogenomics into drug development. Pharmacogenomics3, 453–467 (2002).
- Lesko LJ, Atkinson AJ. Use of biomarkers and surrogate endpoints in drug development and regulatory decision making: criteria, validation, strategies. Annu. Rev. Pharmacol. Toxicol.41, 347–366 (2001).
- Dunn N, Mann RD. Prescription-event and other forms of epidemiological monitoring of side-effects in the UK. Clin. Exp. Allergy29, 217–239 (1999).
- Jones TC. Call for a new approach to the process of clinical trials and drug registration. BMJ322, 920–923 (2001).
- Verbeke G, Molenberghs G. Linear Mixed Models for Longitudinal Data. Springer-Verlag, NY, USA (2000).
- Heise C, Sampson-Johannes A, Williams A, McCormick F, Von Hoff DD, Kirn DH. ONYX015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efcacy that can be augmented by standard chemo-therapeutic agents. Nat. Med.3, 639–645 (1997).
- Prentice RL. Surrogate endpoints in clinical trials: denitions and operational criteria. Stat. Med.8, 431–440 (1989).
- Fleming TR, Prentice RL, Pepe MS, Glidden D. Surrogate and auxiliary endpoints in clinical trials, with potential applications in cancer and AIDS research. Stat. Med.13, 955–968 (1994).
- Freedman LS, Graubard BI, Schatzkin A. Statistical validation of intermediate endpoints for chronic diseases. Stat. Med.11, 167–178 (1992).
- Buyse M, Molenberghs G. The validation of surrogate endpoints in randomized experiments. Biometrics54, 1014–1029 (1998).
- Buyse M, Molenberghs G, Burzykowski T, Renard D, Geys H. The validation of surrogate endpoints in meta-analyses of randomized experiments. Biostatistics1, 49–67 (2000).
- Daniels MJ, Hughes MD. Meta-analysis for the evaluation of potential surrogate markers. Stat. Med.16, 1515–1527 (1997).
- Renard D, Geys H, Molenberghs G, Burzykowski T, Buyse M. Validation of surrogate endpoints in multiple randomized clinical trials with discrete outcomes. Biom. J.44, 921–935 (2002).
- Burzykowski T, Molenberghs G, Buyse M, Geys H, Renard D. Validation of surrogate endpoints in multiple randomized clinical trials with failure-time endpoints. Appl. Stat.50, 405–422 (2001).
- Buyse M, Thirion P, Carlson RW, Burzykowski T, Molenberghs G, Piedbois P; for the Meta-Analysis Group In Cancer. Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: a meta-analysis. Lancet356, 373–378 (2000).
- Alonso A, Geys H, Molenberghs G, Kenward MG. Validation of surrogate markers in multiple randomized clinical trials with repeated measurements: canonical correlation approach. Biometrics60, 845–853 (2004).
- Alonso A, Molenberghs G. Surrogate marker evaluation from an information theoretic perspective. Biometrics63, 180–186 (2007).
- Chen H, Geng Z, Jia J. Criteria for surrogate end points. J. R. Stat. Soc. Ser. B69, 919–932 (2007).
- Frangakis CE, Rubin DB. Principal stratication in causal inference. Biometrics58, 21–29 (2002).
- Burzykowski T, Buyse M, Yothers G, Sakamoto J, Sargent D. Exploring and validating surrogate endpoints in colorectal cancer. Lifetime Data Anal.14, 54–64 (2008).